Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Disease × Lenalidomide × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 155 Lymphoma, Large B-Cell, Diffuse 37 Leukemia, Lymphocytic, Chronic, B-Cell 35 Recurrence 25 Neoplasms, Plasma Cell 24 Lymphoma, Mantle-Cell 20 Lymphoma, Follicular 20 Lymphoma 20 Leukemia 16 Lymphoma, B-Cell, Marginal Zone 15 Lymphoma, Non-Hodgkin 13 Leukemia, Myeloid, Acute 11 Myelodysplastic Syndromes 8 Smoldering Multiple Myeloma 7 Lymphoma, B-Cell 6 Immunoglobulin Light-chain Amyloidosis 6 Waldenstrom Macroglobulinemia 5 Neoplasms 5 Neoplasm, Residual 5 Renal Insufficiency 4 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Leukemia, Myelomonocytic, Chronic 4 Hodgkin Disease 4 Lymphoma, T-Cell, Peripheral 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, T-Cell 3 Leukemia, Plasma Cell 3 Uveal Melanoma 2 Sezary Syndrome 2

Interventions

Prednisone 2 Melphalan 2 Cytarabine 2 venetoclax 1 pembrolizumab 1 ofatumumab 1 obinutuzumab 1 ioflupane 1 ibrutinib 1 gossypol acetic acid 1 gilteritinib 1 fluorocholine 1 fluciclovine F-18 1 deltacortene 1 daratumumab 1 aflibercept 1 Temozolomide 1 Quality of Life 1 Paclitaxel 1 Oncolytic Virotherapy 1 Octreotide 1 Mitoxantrone 1 Methylene Blue 1 Lenalidomide 1 Gemtuzumab 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 Doxorubicin 1 Docetaxel 1 Daunorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01160107 2023-06-29

RP_MPR

Fondazione EMN Italy Onlus

Phase 2 Completed

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡